Contract facts
UnrestrictedNo full NAICS 541714 intel page yet. Browse NAICS intelligence
To Advance the Lead Universal Influenza Vaccine Candidate Through a Phase I Clinical Study and to Evaluate Safety and L… is a federal Unrestricted award for National Institutes Of Health Niaid held by Versatope Therapeutics, Inc. Estimated value $16.8M ($9.5M obligated). Current period of performance ends Aug 31, 2027. Last award drew 12 bidders. Place of performance: LOWELL MA. Related solicitation HHSNIHNIAIDBAA2018.
To advance the lead universal influenza vaccine candidate through a phase i clinical study and to evaluate safety and long-term immunogenicity with one and / or two immunizations. Latest action is a modification.
Recompete timing
PublicCurrent PoP ends Aug 31, 2027 (297 days remaining). Agencies typically plan 12–18 months ahead — at 9.8 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 75N93019C00060? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordVersatope Therapeutics, Inc — $7.7M obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75N93019C00060?
75N93019C00060 (Advance the lead universal influenza vaccine) is a National Institutes Of Health Niaid award with a potential value of $16.8M, currently held by Versatope Therapeutics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75N93019C00060?
National Institutes Of Health Niaid awarded 75N93019C00060 to Versatope Therapeutics, Inc (potential $16.8M).
Who is the incumbent on 75N93019C00060?
Versatope Therapeutics, Inc is the incumbent with $7.7M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2027.
When does Versatope Therapeutics, Inc’s 75N93019C00060 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75N93019C00060? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by contract number; task orders appear as independent rows.